Market Place
Sourcing Support
Vanda Seek FDA Review of CDER Director’s Hetlioz Generic Approval
21 Aug 2025 //
PR NEWSWIRE
Vanda Pharma publishes for Charcot-Marie-Tooth disease type 2S
24 Feb 2025 //
PR NEWSWIRE
Future Pak withdraws offer to buy Vanda Pharmaceuticals
27 Jun 2024 //
REUTERS
Vanda Pharma Confirms Revised Unsolicited Takeover Proposal From Future Pak
13 Jun 2024 //
PR NEWSWIRE
Cycle Unveils $8/Share All-Cash Proposal To Acquire Vanda
06 Jun 2024 //
BUSINESSWIRE
Vanda Confirms Unsolicited Interest From Cycle Group
06 Jun 2024 //
PR NEWSWIRE
Vanda At Jefferies 2024 Global Healthcare Conference
30 May 2024 //
PR NEWSWIRE
Vanda Pharmaceuticals Announces Presentations at SLEEP 2024
30 May 2024 //
PR NEWSWIRE
Vanda Takeover Proposal Rejected: Best Interest Determination By Board
24 May 2024 //
PR NEWSWIRE
Vanda Reports Positive Phase 3 Results For Tradipitant In Motion Sickness
15 May 2024 //
PR NEWSWIRE
Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
08 May 2024 //
PR NEWSWIRE
Future Pak Increases Vanda Bid With CVRs, $7.25-$7.75 Per Share
07 May 2024 //
BUSINESSWIRE
Vanda Confirms Revised Future Pak Takeover Bid
07 May 2024 //
PR NEWSWIRE
Vanda To Announce Q1 2024 Financial Results On May 8
30 Apr 2024 //
PR NEWSWIRE
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
23 Apr 2024 //
REUTERS
Vanda Pharmaceuticals Adopts Stockholder Rights Plan
17 Apr 2024 //
PR NEWSWIRE
Vanda Pharmaceuticals Rejects Unsolicited Takeover Proposals
17 Apr 2024 //
PR NEWSWIRE
Vanda Fanapt Receives FDA Approval for the Acute Treatment of Bipolar I Disorder
02 Apr 2024 //
PR NEWSWIRE
FDA denies hearing to Vanda on jet lag indication for sleep disorder drug
06 Mar 2024 //
ENDPTS
Vanda Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
07 Feb 2024 //
PR NEWSWIRE
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ
05 Feb 2024 //
PR NEWSWIRE
Vanda takes issue with FDA`s relay of deficiencies for new Hetlioz indication
05 Feb 2024 //
ENDPTS
Vanda Receives FDA Approval to Proceed with Investigational New Drug VTR-297
31 Jan 2024 //
PR NEWSWIRE
Vanda to Announce Fourth Quarter and Full Year 2023 Financial Results
31 Jan 2024 //
PR NEWSWIRE
Court Orders FDA to Resolve Vanda`s Jet Lag Hearing Request by March 5, 2024
30 Jan 2024 //
PR NEWSWIRE
Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY
25 Jan 2024 //
PR NEWSWIRE
Vanda Receives FDA Approval to Proceed with Investigational New Drug VCA-894A
23 Jan 2024 //
PR NEWSWIRE
Federal Court Allows Vanda`s Lawsuit to Proceed Against the U.S. FDA
19 Jan 2024 //
PR NEWSWIRE
Vanda Pharma announces the publication of Efficacy and Safety of Iloperidone
17 Jan 2024 //
PR NEWSWIRE
Vanda Announces Participation in the J.P. Morgan Healthcare Conference
04 Jan 2024 //
PR NEWSWIRE
J&J unloads certain Ponvory rights to Vanda for $100M
08 Dec 2023 //
FIERCE PHARMA
Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY
07 Dec 2023 //
PR NEWSWIRE
Vanda Announces that FDA Accepts NDA for Tradipitant for Gastroparesis
05 Dec 2023 //
PR NEWSWIRE
Vanda Pharma Announces Participation at November 2023 Investor Conferences
09 Nov 2023 //
PR NEWSWIRE
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
PR NEWSWIRE
Vanda to Announce Third Quarter 2023 Financial Results on November 8, 2023
01 Nov 2023 //
PR NEWSWIRE
Vanda Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation
20 Oct 2023 //
PR NEWSWIRE
Vanda Announces Participation in Jefferies Inaugural Biotech CNS/Neuro Summit
05 Oct 2023 //
PR NEWSWIRE
Vanda Announces Participation in H.C. Wainwright Global Investment Conference
06 Sep 2023 //
PR NEWSWIRE
Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results
27 Jul 2023 //
PR NEWSWIRE
Vanda Pharma to Announce Second Quarter 2023 Financial Results on July 27, 2023
20 Jul 2023 //
PR NEWSWIRE
Vanda Announces Participation in the Jefferies 2023 Global Healthcare Conference
05 Jun 2023 //
PR NEWSWIRE
Vanda Pharmaceuticals Announces Presentations at SLEEP 2023
01 Jun 2023 //
PR NEWSWIRE
Vanda Reports Results from a Phase III study of Tradipitant in Motion Sickness
25 May 2023 //
PR NEWSWIRE
Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Appeal
10 May 2023 //
PR NEWSWIRE
Vanda Pharmaceuticals Announces Presentations at DDW 2023
04 May 2023 //
PR NEWSWIRE
Vanda Pharmaceuticals Reports 1Q 2023 Financial Results
03 May 2023 //
BUSINESSWIRE
Vanda Sues Federal Government for Misappropriation of Trade Secrets
02 May 2023 //
PR NEWSWIRE
Vanda Pharmaceuticals to Announce 1Q 2023 FYR on May 3, 2023
27 Apr 2023 //
PR NEWSWIRE
Vanda Prevails in Jet Lag Litigation Against the FDA
29 Mar 2023 //
PR NEWSWIRE
Vanda Pharma Reports Fourth Quarter and Full Year 2022 Financial Results
08 Feb 2023 //
PR NEWSWIRE
Vanda Pharmaceuticals to Announce Fourth Quarter Financial Results
01 Feb 2023 //
PR NEWSWIRE
Solicitor General Recommends That Supreme Court Deny Certiorari Hikma v. Vanda
09 Dec 2019 //
PATENTDOCS
Hetlioz®(Tasimelteon): Vanda Pharmaceuticals v. MSN Pharmaceuticals Inc
07 May 2018 //
PATENT LITIGATION
Hetlioz®(Tasimelteon): Vanda Pharmaceuticals v. Apotex
07 May 2018 //
PATENT LITIGATION
